Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.59 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.59 |
| ▸ | KMO | O15229 | 2/20 | 0.55 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.54 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.47 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.47 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL981462 | 0.85 | CYP19A1 (0.64) | PIM1PIM2S1PR1MAOAMAOB | |
| SCHEMBL977340 | 0.84 | FFAR1 (0.58) | MAOBHDAC6FFAR1 | |
| SCHEMBL11565251 | 0.83 | TNKS (0.55) | PIM1PIM2KMOMKNK1MKNK2 | |
| SCHEMBL11565093 | 0.81 | TNKS (0.55) | KMOMKNK1MKNK2MAOAMAOB | |
| SCHEMBL14677366 | 0.81 | KDM4E (0.65) | PIM1PIM2S1PR1MAOAMAOB | |
| SCHEMBL15867533 | 0.79 | CYP19A1 (0.51) | PIM1PIM2MAOAMAOBALDH1A1 | |
| SCHEMBL12872332 | 0.77 | KDM4E (0.68) | ALDH1A1HDAC6KDM4E | |
| SCHEMBL30402815 | 0.77 | KDM4E (0.68) | ALDH1A1HDAC6KDM4E | |
| SCHEMBL29993564 | 0.76 | MAOB (0.54) | MAOAMAOBALDH1A1KDM4EPGR | |
| SCHEMBL2960606 | 0.76 | MAOB (0.54) | MAOAMAOBALDH1A1KDM4EPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2011-01-27 | — | — | US | disclosed |
| EP-2217566-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | AstraZeneca AB (SE) | 2010-08-18 | — | — | EP | disclosed |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | US | disclosed |
| WO-2009064250-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 065 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064251-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | PTGER1, CYP3A5, SULT1E1 | PIM1 1861/4885PIM2 2975/4885KMO 830/4885 |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | CYP2D6, PTGER1, CYP2B6 | PIM1 1947/4885PIM2 2904/4885KMO 1255/4885 |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | CYP2D6, PTGER1, CYP2B6 | PIM1 1947/4885PIM2 2904/4885KMO 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.